News | June 16, 2022
Enko advances Enkompass platform through DNA-encoded library technology
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Large datasets will train machine learning models and speed up agile discovery of novel crop protection solutions
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Subscribe To Our Newsletter & Stay Updated
